GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shukra Pharmaceuticals Ltd (BOM:524632) » Definitions » Shares Outstanding (EOP)

Shukra Pharmaceuticals (BOM:524632) Shares Outstanding (EOP) : 43.8 Mil (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Shukra Pharmaceuticals Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Shukra Pharmaceuticals's shares outstanding for the quarter that ended in Mar. 2024 was 43.8 Mil.

Shukra Pharmaceuticals's quarterly shares outstanding increased from Dec. 2023 (43.8 Mil) to Mar. 2024 (43.8 Mil). It means Shukra Pharmaceuticals issued new shares from Dec. 2023 to Mar. 2024 .

Shukra Pharmaceuticals's annual shares outstanding increased from Mar. 2023 (15.7 Mil) to Mar. 2024 (43.8 Mil). It means Shukra Pharmaceuticals issued new shares from Mar. 2023 to Mar. 2024 .


Shukra Pharmaceuticals Shares Outstanding (EOP) Historical Data

The historical data trend for Shukra Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shukra Pharmaceuticals Shares Outstanding (EOP) Chart

Shukra Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.09 30.09 30.09 15.66 43.80

Shukra Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.66 15.66 43.84 43.79 43.80

Competitive Comparison of Shukra Pharmaceuticals's Shares Outstanding (EOP)

For the Drug Manufacturers - Specialty & Generic subindustry, Shukra Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shukra Pharmaceuticals's Shares Outstanding (EOP) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shukra Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Shukra Pharmaceuticals's Shares Outstanding (EOP) falls into.



Shukra Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Shukra Pharmaceuticals  (BOM:524632) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Shukra Pharmaceuticals Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Shukra Pharmaceuticals's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Shukra Pharmaceuticals (BOM:524632) Business Description

Traded in Other Exchanges
N/A
Address
Judges Bunglow Road, Bodakdev, 3rd Floor, Veer House, Opposite WIAA Office, Ahmedabad, GJ, IND, 380054
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments; pharmaceutical and Laboratory. Its product portfolio includes antibiotics, antibiotics, quinolones, macrolides, anti-bacterial, anti-fungal, anti-malarial, anti-viral, antiprotozoal, anti-anthelmintic, anti-depressant, anti-manic, anti-emetic, beta-blockers, analgesic, muscle relaxants, anti-tuberculosis, vitamin products, anti-allergic, corticosteroids, hyper and hypoglycemic, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.

Shukra Pharmaceuticals (BOM:524632) Headlines

No Headlines